Serum alpha 2-macroglobulin levels in diabetes.

Area of Science:

• Biochemistry
• Endocrinology
• Clinical Medicine

Background:

• Alpha 2-macroglobulin (A2M) is a key proteinase inhibitor in serum.
• Diabetes mellitus is a complex metabolic disorder with various systemic complications.
• Previous studies suggested altered A2M levels in diabetic patients.

Purpose of the Study:

• To quantify serum alpha 2-macroglobulin levels in diabetic patients.
• To compare A2M levels with age- and sex-matched healthy controls.
• To investigate the correlation of A2M levels with clinical parameters in diabetes.

Main Methods:

• Quantitative radial immunodiffusion was used for A2M measurement.
• Diabetic patients were analyzed based on age, sex, disease duration, treatment, and complications.
• Multiple regression analysis was employed to identify significant contributing factors.

Main Results:

• Diabetic patients exhibited significantly higher serum A2M levels than controls.
• The difference in A2M levels was most pronounced in the extreme age groups.
• Good glycemic control and the presence of retinopathy were significantly associated with A2M levels.

Conclusions:

• Serum alpha 2-macroglobulin is elevated in diabetes mellitus.
• Age, glycemic control, and retinopathy are significant determinants of A2M levels in diabetics.
• A2M may serve as a potential biomarker in managing diabetic complications.